Background: Prolonged labor is one of the most important risk factors
for perinatal compromise and, if caused by obstructed labor, it carries
the risk of uterine rupture, postpartum hemorrhage (PPH), puerperal
sepsis, and maternal death. Objective: To determine whether or not
hyoscine butylbromide shortens the stages of labor, without an increase
in maternal or neonatal complications. Method: In single-blinded
randomized clinical trial study , 188 multiparas women in active phase
of labor who were admitted to Shahid Sadoughi Hospital from October
2006 to April 2007 in Yazd - Iran , were evaluated . They were divided
hyoscine group (n = 94) received 20mg (1ml) of hyoscine and control
group (n = 94) received 1 ml of normal saline was given as placebo,
intravenously. The effects of hyoscine in shortening labor time; and
neonatal Apgar score was compared. Results: Duration of the first
(mean± SD: 186.8 ± 125.6 minutes vs. 260.4 ± 120.9
minutes, p= 0.00 1) and second stage of labor (mean± SD: 20.0
± 8.1minutes vs. 25.8 ± 9.4 minutes, p= 0.03) was shorter in
hyoscine group. Frequency of cesarean section and mean of neonatal
Apgar score at minutes of one and 5 were not different in both groups.
No serious adverse events were seen in the two groups. Conclusion:
Injection of hyoscine in active phase of labor can be effective in
shortening of labor without any adverse effect on mother and fetus